Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Noriko Kohyama is active.

Publication


Featured researches published by Noriko Kohyama.


Journal of Pharmacy and Pharmacology | 2005

Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7])

Yasuna Kobayashi; Naomi Ohshiro; Ryoko Sakai; Masayuki Ohbayashi; Noriko Kohyama; Toshinori Yamamoto

Human organic anion transporter 2 (hOat2 [SLC22A7]) is highly expressed in the human liver. Although localization, gene expression, substrate specificity and transport mechanisms of other human Oat isoforms such as human Oat1 (hOat1), human Oat3 (hOat3) and human Oat4 (hOat4) have been elucidated, information concerning human Oat2 (hOat2) is less defined. The objective of this study was to provide further information on the transport mechanism and substrate specificity of hOat2. When expressed in Xenopus laevis oocytes, the transport of organic compounds mediated by hOat2 was not affected by the replacement of extracellular sodium with lithium, choline and mannitol. The uptake of estrone sulfate (ES) in hOat2‐expressing oocytes was significantly trans‐stimulated by preloading the oocytes with fumarate and succinate, but not glutarate. Moreover, we observed that hOat2 mediates the transport of bumetanide, ES, glutarate, dehydroepiandrosterone sulfate, allopurinol, prostaglandin E2, 5‐fluorouracil, paclitaxel and L‐ascorbic acid. These compounds are identified for the first time as hOat2 substrates. A wide range of structurally unrelated organic compounds inhibited the hOat2‐mediated uptake of tetracycline, except for sulfobromophthalein. All of these findings indicate that hOat2 is a sodium‐independent multi‐specific organic anion/dimethyldicarboxylate exchanger. Our present findings thus provide further insights into the role of hOat2 in hepatic drug transport.


Drug Metabolism and Disposition | 2005

FUNCTIONAL CHARACTERIZATION OF HUMAN MONOCARBOXYLATE TRANSPORTER 6 (SLC16A5)

Yuichi Murakami; Noriko Kohyama; Yasuna Kobayashi; Masayuki Ohbayashi; Hisakazu Ohtani; Yasufumi Sawada; Toshinori Yamamoto

Human monocarboxylate transporter 6 (MCT6) has recently been isolated, and its tissue distribution has been established at the mRNA level, but its functional properties remain unknown. The aim of this study is to investigate the transport properties of MCT6. When expressed in Xenopus laevis oocytes, MCT6 transported [3H]bumetanide in a pH- and membrane potential-sensitive but not proton gradient-dependent manner, with the Kt value of 84 μM. Furthermore, MCT6 transported various drugs such as probenecid and nateglinide. Neither [14C]l-lactic acid nor [3H]l-tryptophan, typical substrates of other MCT isoforms, was transported by MCT6. Four loop diuretics, i.e., furosemide, piretanide, azosemide, and torasemide, thiazides, probenecid, glibenclamide, and nateglinide inhibited the MCT6-mediated uptake of [3H]bumetanide. In contrast, short-chain carboxylic acids, such as l-lactic acid and succinic acid did not inhibit the MCT6-mediated uptake of bumetanide. These results suggest that the substrate specificity of MCT6 is distinct from those of other MCTs. Bumetanide would be a good tool for investigating the functional properties of MCT6. It is probable that MCT6 is involved in the disposition of various drugs, including bumetanide.


Drug Metabolism and Disposition | 2007

Isolation and characterization of polyspecific mouse organic solute carrier protein 1 (mOscp1).

Yasuna Kobayashi; Ayumi Tsuchiya; Tomofumi Hayashi; Noriko Kohyama; Masayuki Ohbayashi; Toshinori Yamamoto

We succeeded in isolating the cDNA-encoding mouse organic solute carrier protein 1 (mOscp1) from a mouse testis cDNA library. mOscp1 consisted of 1137 base pairs that encoded a 379-amino acid protein, and the amino acid sequence was 85% identical to that of human OSCP1 (hOSCP1). Northern blot analysis revealed that the gene coding for mOscp1 is highly expressed in the testis, but not in other tissues. When expressed in Xenopus laevis oocytes, mOscp1 mediated the high-affinity transport of p-aminohippurate (PAH) (Km = 18.8 ± 4.1 μM) with Na+ independence. mOscp1 transported various kinds of structurally dissimilar drugs and chemicals such as probenecid, dehydroepiandrosterone sulfate, and glutarate with some differences in substrate specificity compared with hOSCP1. Cyclophosphamide inhibited the mOscp1-mediated PAH uptake. Immunohistochemical analysis revealed that the mOscp1 protein is localized in the plasma membrane side of Sertoli cells in the testis. Our results indicate that isolated mOscp1 is a polyspecific organic solute carrier protein and may be a key molecule for the testicular handling of organic solutes.


Drug Metabolism and Disposition | 2013

Characterization of monocarboxylate transporter 6: expression in human intestine and transport of the antidiabetic drug nateglinide

Noriko Kohyama; Hisae Shiokawa; Masayuki Ohbayashi; Yasuna Kobayashi; Toshinori Yamamoto

Monocarboxylate transporter (MCT) 6, encoded by SLC16A5, is a member of the monocarboxylate transporter family. Nateglinide, an oral hypoglycemic agent, quickly reaches the maximal serum concentration after its premeal administration. Although the functional existence of uptake systems for nateglinide in the intestine has been demonstrated, these transport systems have not yet been identified at the molecular level. The aim of this study was to demonstrate the localization of MCT6 in the human small intestine and characterize the transport properties of nateglinide via MCT6. Immunohistochemical analysis of the human small intestine revealed that anti-MCT6 antiserum stained the luminal side of the epithelial cells. When expressed in Xenopus laevis oocytes, MCT6-mediated uptake of [14C]nateglinide was sensitive to extracellular pH and membrane potential. Furthermore, the Kt value of nateglinide (45.9 μM) for MCT6 was lower than those previously reported in Caco-2 cells and rat intestinal brush-border membrane vesicles. In addition, probenecid, fluorescein, valproic acid, and salicylic acid, which are inhibitors of nateglinide uptake in Caco-2 cells and rat intestine, did not inhibit the uptake of nateglinide via MCT6. These results suggest that MCT6 may play a role in the intestinal absorption of nateglinide, although other transporters are also likely involved.


Meta Gene | 2014

Genetic polymorphism of the human organic solute carrier protein 1 (hOSCP1) gene in Japanese patients with non-viral liver carcinoma.

Mayumi Toda; Yasuna Kobayashi; Tomotake Koizumi; Koji Saito; Masayuki Ohbayashi; Noriko Kohyama; Takeshi Aoki; Masahiko Murakami; Hajime Yasuhara; Toshinori Yamamoto

Human organic solute carrier protein 1 (hOSCP1) is a Na+-independent multispecific organic solute transporter. To date, several studies have revealed that gene mutations of the transporters are likely to be associated with some diseases; however, there are no data concerning the genetic polymorphism of the hOSCP1 gene in Japanese patients with non-viral liver carcinoma (LC). In the present study, we isolated genomic DNA from a normal portion of LC, and analyzed 41 single nucleotide polymorphisms (SNPs) chosen from a database of SNPs (dbSNPs). We found genotype frequencies for 2 non-synonymous SNPs [rs34409118 (Thr131 → Ala) and rs1416840 (Ile219 → Thr)] and 1 synonymous SNP [rs16822954 (Ser193 → Ser)] to be statistically significant when compared with dbSNPs. No statistical significance was observed in rs2275477 (Gly307 → Arg) in the hOSCP1 gene. With respect to the allele frequency, we also observed rs34409118 to be statistically significant. Interestingly, we found that non-viral LC patients do not carry heterozygous mutations in rs1416840 (A/G) and rs16822954 (A/G), suggesting that a non-carrier of heterozygous mutations in these two SNPs might be a biomarker for susceptibility for non-viral LC in Japanese. Further analyses of patients with hOSCP1 variants may elucidate the relationship between the hOSCP1 gene and susceptibility of non-viral LC in Japanese patients.


Drug Metabolism and Disposition | 2010

Activation of Cyclosporin A Transport by a Novel λ Light Chain of Human Ig Surface Antigen-Related Gene in Xenopus laevis Oocytes

Yasuna Kobayashi; Takahiro Umemoto; Masayuki Ohbayashi; Noriko Kohyama; Yutaka Sanada; Toshinori Yamamoto

In the present study, we isolated and determined the pharmacological characteristics of a novel gene encoding the λ light chain of human Ig surface antigen-related gene (IgLC-rG). The isolated cDNA consisted of 693 base pairs that encoded a 232-amino acid protein. Northern blot analysis revealed that the IgLC-rG mRNA is expressed in the adult spleen and small intestine but not in fetal tissues. When expressed in Xenopus laevis oocytes, IgLC-rG mediated the high-affinity transport of [3H]cyclosporin A (CsA) (Km = 189.7 ± 123.5 nM) in a sodium-dependent manner; however, other organic solutes such as p-aminohippuric acid and TEA were not transported via IgLC-rG. The transport of [3H]CsA by IgLC-rG was sensitive to pH. The uptake of [3H]CsA was trans-stimulated by CsA and GSH. Immunohistochemical analysis revealed that the IgLC-rG protein is localized at the brush border membrane in the human small intestine. Although the isolated IgLC-rG gene is a member of the human Ig λ light chain surface antigen superfamily, our findings suggest that IgLC-rG functions as a novel transport peptide responsible for CsA in the human body. Our results should provide insight into the novel function of membrane-bound proteins, such as Igs.


Drug Metabolism and Disposition | 2005

POSSIBLE INVOLVEMENT OF ORGANIC ANION TRANSPORTER 2 ON THE INTERACTION OF THEOPHYLLINE WITH ERYTHROMYCIN IN THE HUMAN LIVER

Yasuna Kobayashi; Ryoko Sakai; Naomi Ohshiro; Masayuki Ohbayashi; Noriko Kohyama; Toshinori Yamamoto


Drug Metabolism and Disposition | 2004

Renal transport of organic compounds mediated by mouse organic anion transporter 3 (MOAT3): Further substrate specificity of MOAT3

Yasuna Kobayashi; Naomi Ohshiro; Ayumi Tsuchiya; Noriko Kohyama; Masayuki Ohbayashi; Toshinori Yamamoto


Pharmaceutical Research | 2007

Effects of various methoxyflavones on vincristine uptake and multidrug resistance to vincristine in P-gp-overexpressing K562/ADM cells

Hisakazu Ohtani; Tomomi Ikegawa; Youko Honda; Noriko Kohyama; Satoshi Morimoto; Yukihiro Shoyama; Motoharu Ju-ichi; Mikihiko Naito; Takashi Tsuruo; Yasufumi Sawada


Journal of Toxicological Sciences | 2010

Induction of pulmonary fibrosis by methotrexate treatment in mice lung in vivo and in vitro

Masayuki Ohbayashi; Masanori Suzuki; Yoshiki Yashiro; Sayaka Fukuwaka; Masako Yasuda; Noriko Kohyama; Yasuna Kobayashi; Toshinori Yamamoto

Collaboration


Dive into the Noriko Kohyama's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge